Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections

Transplant Infectious Disease

Volumn 9, Issue 2, 2007, Pages 89-96

  Mullane, K ^a,b   Toor, A A ^a   Kalnicky, C ^a   Rodriguez, T ^a   Klein, J ^a   Stiff, P ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Invasive fungal infection; Posaconazole; Refractory

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CARMUSTINE; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEPSIPEPTIDE; DEXAMETHASONE; ETOPOSIDE; FLUCONAZOLE; GANCICLOVIR; IDARUBICIN; IMIPENEM; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MITOXANTRONE; POSACONAZOLE; PREDNISONE; SULTAMICILLIN; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALTERNARIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CANCER PATIENT; CANDIDIASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROBACTER INFECTION; FEMALE; HEART DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTIOUS DIARRHEA; LUNG INFECTION; LUNG INFILTRATE; MALE; MAXILLA SINUSITIS; MUCORMYCOSIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYCOSIS; NEUTROPENIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PAECILOMYCES LILACINUS; PERICARDIUM; PNEUMONIA; PRIORITY JOURNAL; SALVAGE THERAPY; SINUSITIS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; ZYGOMYCETES;

ADULT; ANTIBIOTICS, ANTIFUNGAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYCOSES; PROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 34247628595     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2007.00208.x     Document Type: Article

References (53)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002 34: 909 917.
2. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003 102: 827 833.
3. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001 33: 139 144.
4. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003 101: 3365 3372.
5. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002 94: 3230 3246.
6. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000 108: 282 289.
7. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003 138: 705 713.
8. Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999 28: 331 340.
9. Marty FM, Cosimi L, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004 350: 950 952.
10. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004 39: 584 587.
11. Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005 40: e35 e37.
12. Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect 2002 17: 113 120.
13. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003 16: 607 612.
14. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004 38: 1237 1242.
15. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001 33: 1692 1696.
16. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005 191: 1350 1359.
17. Marco F, Pfaller MA, Messer SA, Jones RN. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia 1998 141: 73 77.
18. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006 50: 2009 2015.
19. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002 46: 1581 1582.
20. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001 45: 2862 2864.
21. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998 36: 2950 2956.
22. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003 51: 45 52.
23. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2004 48: 201 205.
24. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003 47: 3149 3154.
25. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003 41: 3623 3626.
26. Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI). In: Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, October 30-November 2, 2004; 412 [Abstract M-669].
27. Segal BH, Barnhart LA, Anderson VL, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005 40: 1684 1688.
28. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006 50: 658 666.
29. Stevens DA, Rendon A, Gaona V, et al. Posaconazole (POS) therapy for chronic refractory coccidioidomycosis. In: Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, October 30-November 2, 2004; [Abstract M-663].
30. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005 56: 745 755.
31. Restrepo A, Clark B, Graham DR, et al. Successful treatment of disseminated and acute pulmonary histoplasmosis with posaconazole. In: Program and Abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, Illinois, September 14-17, 2003; [Abstract M-973].
32. Herbrecht R, Kessler R, Kravanja C, Meyer MH, Waller J, Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2003 23: 1451 1454.
33. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006 42: 1398 1403.
34. Proia LA. The efficacy of posaconazole for chronic refractory Alternaria infection: a case study. In: Program and Abstracts of the 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005.
35. Garbino J, Uckay I, Amini K, Puppo M, Richter M, Lew D. Absidia posttraumatic infection: successful treatment with posaconazole. J Infect [serial online] 2005 51: e135 e138. Accessed November 18, 2005.
36. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34: 7 14.
37. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997 25: 551 573.
38. Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004 10: 494 503.
39. Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998 26: 1098 1103.
40. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole therapy for refractory invasive zygomycosis. Antimicrob Agents Chemother 2006 50: 126 133.
41. Pfaller MA, Messer SA, Hollis RJ, Jones RN the SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002 46: 1032 1037.
42. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001 45: 857 869.
43. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003 47: 3647 3650.
44. Tobón A, Correa AL, Arango M, de Bedout C, Restrepo A. Posaconazole therapy for severe abdominal candidiasis: a case report. Revista Iberoamericana de Micologia 2004 21: 78 80.
45. Tobón AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003 36: 1488 1491.
46. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004 48: 3543 3551.
47. Al-Abdely HM, Alkhunaizi A, Al-Tawfiq J, Hassonah M, Rinaldi MG, Sutton DA. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 2005 43: 91 95.
48. Anstead G, Corcoran G, Lewis JS, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005 40: 1770 1776.
49. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002 34: 1648 1650.
50. Negroni R, Helou SH, Petri N, Robles AM, Arechavala A, Bianchi MH. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 2004 38: e15 e20.
51. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006 42: 1726 1734.
52. Hamza NS, Ghannoum MA, Lazarus HM. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004 34: 377 389.
53. Sansone A, Belle D, Statkevich P, et al. Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy volunteers. In: Program and Abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, Illinois, September 14-17, 2003; 33 [Abstract A-1603].